Wellmarker Bio

Wellmarker Bio Develops Biomarker-Based Cancer DrugWellmarker Bio, leveraging its accumulated development experience and technology, has developed a biomarker-based cancer drug. They have established a new drug development infrastructure, including synthesis, bioresearch, and management support centers, utilizing the R&D infrastructure of Seoul's Asan Medical Center in Korea. Their focus is on developing novel drugs to overcome resistance to existing treatments. Additionally, they are dedicated to creating first-in-class biomarker-based drugs to address the medical needs of various cancers, such as colorectal cancer, lung cancer, and liver cancer.